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Abstract Deep brain stimulation (DBS) of the fornix has
gained interest as a potential therapy for advanced treat-
ment-resistant dementia, yet the mechanism of action
remains widely unknown. Previously, we have reported
beneficial memory effects of fornix DBS in a scopolamine-
induced rat model of dementia, which is dependent on
various brain structures including hippocampus. To eluci-
date mechanisms of action of fornix DBS with regard to
memory restoration, we performed c-Fos immunohisto-
chemistry in the hippocampus. We found that fornix DBS
induced a selective activation of cells in the CA1 and CA3
subfields of the dorsal hippocampus. In addition, hip-
pocampal neurotransmitter levels were measured using
microdialysis before, during and after 60 min of fornix
DBS in a next experiment. We observed a substantial
increase in the levels of extracellular hippocampal acetyl-
choline, which peaked 20 min after stimulus onset.
Interestingly, hippocampal glutamate levels did not change
compared to baseline. Therefore, our findings provide first
experimental evidence that fornix DBS activates the hip-
pocampus and induces the release of acetylcholine in this
region.
Keywords Deep brain stimulation  Memory  Fornix 
Hippocampus  Acetylcholine
Introduction
Dementia is a major threat to human population. The
World Health Organization estimates that 35.6 million
people suffer from dementia, a number that is anticipated
to triple by 2050 (Batsch and Mittelman 2012). The most
common form of dementia is Alzheimer’s disease (AD),
accounting for 60–80 % of all cases. So far there are no
known treatments available that cure or delay the pro-
gression of AD. Current pharmacological treatments are
not effective for every patient and only alleviate symp-
toms temporarily (Rosini et al. 2008; Thies and Bleiler
2011).
Recently, the application of DBS to reduce or delay
the progression of memory loss in AD has shown to be
effective. In particular, the convergence of the latest
observations in humans and rats pinpoints that DBS of
the fornix can restore memory loss (Hamani et al. 2008;
Hescham et al. 2013; Laxton et al. 2010). In our own
experiments (Hescham et al. 2013), fornix DBS reduced
memory deficits induced by the muscarinic receptor
antagonist scopolamine in a rat model. In this scopo-
lamine-induced rat model of memory impairment, vari-
ous brain structures including the hippocampus are
affected (Hescham et al. 2014). The mechanism of action
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of fornix DBS is not well understood but the latter
suggests an involvement of the hippocampus and
acetylcholine.
In the present study, we therefore investigated the
effects of fornix DBS on the hippocampus with a dual
approach. First, we evaluated c-Fos expression in the
dorsal hippocampus. The immediate early gene c-Fos is
an indirect marker of neuronal activation and can be
even used to map long-term activation (Budzikowski
et al. 1998; Jahanshahi et al. 2013). Second, we inves-
tigated the effect of fornix DBS on levels of hip-
pocampal acetylcholine as well as glutamate;
neurotransmitters which are widely acknowledged as
important for memory functions (Klinkenberg et al.
2011; Micheau and Marighetto 2011).
Materials and methods
Experimental design
This study consists of two experiments:
Experiment 1 Male Sprague–Dawley rats (Charles
River, Sulzfeld, Germany) were either assigned to the
fornix DBS (n = 5) or sham (n = 5) group. Electrode
implantations were performed as described previously
(Hescham et al. 2013). DBS electrodes were implanted at
the site of the fornix (coordinates from bregma according
to the rat brain atlas of Paxinos and Watson (Paxinos and
Watson 1998): AP: -1.8 mm; ML: 1.3 mm; DV:
-8.0 mm). It was found that fornix DBS reduced memory
deficits induced by the muscarinic receptor antagonist
scopolamine in a hippocampal-dependent rat model as
reported elsewhere (Hescham et al. 2013). In these same
animals, 1 week later (when scopolamine is no longer
present), rats were stimulated at 100 Hz, 100 lA and
100 ls pulse width for 1 h and allowed to rest for 1 h.
Sham rats were only attached to cables, but not stimulated.
Subsequently, animals were transcardially perfused, first
with Tyrode’s solution and then Somogyi fixative (Somo-
gyi and Takagi 1982). Animal procedures in experiment 1
were approved and carried out in accordance to the Animal
Experiments and Ethics Committee of Maastricht
University.
Experiment 2 To establish whether fornix DBS affects
the neurochemistry in the hippocampus, microdialysis
experiments were carried out in male Sprague–Dawley
rats (Harlan, Bicester, U.K., fornix DBS n = 13 and
sham n = 6) under urethane anesthesia. Animal proce-
dures in experiment 2 were carried out in accordance
with the UK Animals (Scientific Procedures) Act 1986
and associated Home Office guidelines, and with local
ethical approval.
Immunohistochemistry
Following transcardial perfusion in experiment 1, brains
were collected and cut into 30 lm slices on a vibratome
(Leica, Wetzlar, Germany). For immunohistochemistry,
sections were incubated overnight with polyclonal rabbit
anti-c-Fos primary antibody (1:2000; K-25, Santa Cruz
Biotechnology Inc, Santa Cruz, USA) followed by
biotinylated donkey anti-rabbit secondary antibody (1:800;
Jackson Immunoresearch Laboratories Inc., Westgrove,
USA) and avidin–biotin peroxidase complex (1:800, Elite
ABC-kit, Vectastain, Burlingame, CA, USA). The stain-
ing was visualized by 3,30-Diaminobenzidine (DAB)
combined with NiCl2 intensification.
Images were taken at two similar bregma levels using a
U-CMAD-2 digital camera connected to an Olympus AX70
brightfield microscope (analySIS; Imaging System, Mu¨n-
ster, Germany), and evaluated with ImageJ (Image J soft-
ware version 1.38x; NIH, Bethesda, USA). C-Fos-positive
cells in the medial prefrontal cortex and hippocampus were
counted manually by an observer blind to treatment.
In-vivo microdialysis
For experiment 2, rats were anesthetized with 1.3-1.5 g/kg
urethane (ethyl carbamate, Sigma) and mounted in a
stereotaxic frame. DBS electrodes were implanted at the
site of the fornix, and a single cannula microdialysis probe
(CMA11, tip length 2 mm, CMA Microdialysis, Kista,
Sweden) was implanted into the hippocampus (coordinates
from bregma: AP: -4.8 mm; ML: 3 mm; DV: -4.2 mm).
Microdialysis probes were perfused with artificial cere-
brospinal fluid (141 mM NaCl, 5 mM KCl, 0.8 mM
MgCl2, 1.5 mM CaCl2) at a flow rate of 1.5 ll/min (CMA/
100, Carnegie Medicine) for 2 h before dialysate collection
started. Dialysate samples were collected every 20 min,
DBS stimulation time (100 Hz, 100 lA and 100 ls) was
1 h. In total, 10 samples were collected (4 baseline, 3
during stimulation and 3 after stimulation). Samples were
immediately frozen on dry ice and later analyzed with
liquid chromatography/mass spectrometry.
Liquid chromatography/mass spectrometry
All microdialysis samples were analyzed at Eli Lilly and
Company Ltd., Windlesham, U.K. The high-performance
liquid chromatography (HPLC) system consisted of a PAL
HTC-xt autosampler (CTC Analytics AG Zwingen, Switzer-
land), a pair of ShimadzuLC-20ADXRpumpswith aShimadzu
CBM-20A controller and Shimadzu CTO-20AD column oven
(Shimadzu Ltd., Milton Keynes, UK). Injection volume was
10 ll. The chromatographic retention was obtained using an
XBridge BEH Amide column (75 9 2.1 mm, i.d. 2.5 lm;
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Waters Ltd, Elstree, U.K.) at 35 C. The gradient elution was
carried out using acetonitrile and 2 mM ammonium formate,
95:5 and 5:95 (the pH of 3.0 was adjusted with formic acid).
Detection was carried out by an AB Sciex Triple Quad
API5500 mass spectrometer MS (AB Sciex UK Ltd, War-
rington,U.K.),whichoperated inTurboIonSpraymodeusing
a Turbo VTM source and SRM analysis.
Acetylcholine was detected by monitoring the m/z
146.1 ? 87.0 transition and its D4 analog internal standard
at m/z 150.1 ? 91.0 (dwell time: 50 ms, collision energy:
20 V, collision cell exit potential: 4.2 V). Glutamic acid
was detected by monitoring the m/z 148.0 ? 84.0 transi-
tion and its D5 analog internal standard at m/z
153.0 ? 88.0 (dwell time: 50 ms, collision energy: 23 V,
collision cell exit potential: 10 V). Samples were prepared
by 1:10 dilution in internal standard and a single acetyl-
choline calibration curve between 0.10 and 20.0 nM and
glutamic acid curve between 50 and 2000 nM was run at
the end of each batch of samples for quantification.
Verification of DBS electrodes and microdialysis
probes
Sections containing the electrode trajectories from all
animals were collected and mounted on gelatin-coated
glass slides. A standard haematoxylin–eosin staining was
carried out before sections were photographed under bright
field microscopy.
Statistical analysis
For experiment 1, the number of Fos-positive cells was
expressed as percentage of change when compared to sham
(i.e., the average of Fos-positive cells in sham was chosen as
reference value and defined as 100 %). Raw values as well as
percentage scores were normally distributed as assessed by
the Shapiro–Wilk’s test. For better comparison between the
groups, however, we chose to present the percentage scores.
An independent-samples t test was employed and p val-
ues\ 0.05were considered significant.Microdialysis data of
experiment 2were represented as percentage of themean of 4
baseline samples prior to DBS. The effect of fornix DBS on
extracellular acetylcholine and glutamate levels over time
was analyzed by repeated-measures ANOVA followed by
Fisher’s least significant difference (LSD) post hoc test.
Results
Verification of DBS electrodes and microdialysis
probes
The location of all DBS electrodes was verified within the
fornix, and microdialysis probes were all correctly placed
in the dorsal hippocampus. For the current stimulation
settings used, we found no evidence for histological dam-
age as observed by a standard haematoxylin–eosin staining.
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Fig. 1 Representative low-power photomicrographs (scale
bar = 500 lm) of coronal brain sections stained for c-Fos (K-25)
showing the hippocampus of sham (a) and fornix stimulated animals
(b). The high-power photomicrograph insets in the lower left corner
show the CA1 subregion of the hippocampus (scale bar = 50 lm).
c Comparisons were made as percentage increase/decrease with
regard to sham. Fornix DBS rats show increased c-Fos (K-25)
expression in the CA1 and CA3 subregion of the hippocampus when
compared to sham. There was no statistical difference between sham
and DBS groups in the dentate gyrus. *p\ 0.05, independent-
samples t test for fornix DBS vs. sham rats. Data represent
mean ± SEM. DG dentate gyrus, cc corpus callosum
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Immunohistochemistry
We found increased c-Fos expression in the CA1 subregion
for fornix stimulated animals when compared to sham
[t(8) = 4.285; p\ 0.01]. In addition, increased levels of
c-Fos cells in the CA3 subregion were observed in fornix
DBS rats [t(8) = 4.363; p\ 0.01]. There was no statistical
difference between levels of c-Fos expression in the den-
tate gyrus of fornix stimulated and sham rats [t(7) = 0.455;
n.s.; Fig. 1].
In-vivo microdialysis
Fornix DBS for 60 min caused a significant increase in
hippocampal acetylcholine levels in comparison to non-
stimulated controls [repeated-measures ANOVA:
F(1,17) = 6,608; p\ 0.03]. This effect was evident in the
first 20 min of fornix DBS as shown by the LSD post hoc
test (p\ 0.03; Fig. 2a). Acetylcholine levels in other time
points during stimulation as well as after stimulation did
not differ between the groups.
There was no statistical difference for hippocampal
glutamate levels between fornix DBS and sham [repeated-
measures ANOVA: F(1,16) = 0.038; n.s.; Fig. 2b].
Discussion
According to several studies, fornix DBS in AD patients
leads to a decreased rate of cognitive decline (Fontaine
et al. 2013; Laxton et al. 2010); yet, a potential mechanism
of action has not been found. In the present study, we found
that beneficial memory effects of fornix DBS might be
linked to an enhanced neural activity in the CA1 and CA3
subfield, suggesting increased activity of certain neurons in
this region. The CA1 and CA3 subregions of the hip-
pocampus are important for spatial memory (Farovik et al.
2010; Lee et al. 2005). In particular, the CA3 subregion
plays a role in encoding and retrieval of spatial location
sequences and the CA1 contributes to memory encoding by
binding cues to their temporal context, which in turn also
enables retrieval of location sequences (Farovik et al.
2010). Interestingly, a substantial neuronal loss in the CA1
is observed in post-mortem AD brains (West et al. 2004). If
fornix DBS is able to increase neural activity in the CA1
subfield, then it may compensate for reduced neuronal
integrity of this region in AD.
In the etiology of AD, evidence exists for both
cholinergic and glutamatergic involvement (Francis
2005). In the present study, microdialysis data revealed
that hippocampal glutamate levels were not affected by
fornix DBS. A clear connection between glutamate and
memory-related processes is provided by the association
of ionotropic glutamate receptors in the induction of
long-term potentiation. Although memory can be dis-
rupted by blockade of these receptors (e.g., N-methyl-D-
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Fig. 2 Microdialysate acetylcholine (ACh, a) and glutamate
(b) levels of the dorsal hippocampus in anesthetized fornix DBS
(n = 13) and sham rats (n = 6). Horizontal bar stimulation period.
ACh levels were significantly elevated in the fornix DBS group after
20 min of stimulation. No difference in glutamate levels was detected
between fornix DBS and sham. Data points are mean ± SEM
expressed as % of baseline. Mean raw values for baseline ACh were
0.324 nM ± 0.023 and for glutamate 3.05 lM ± 0.24. *p\ 0.05,
repeated-measures ANOVA for fornix DBS vs. sham rats
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aspartate, NMDA) (Morris et al. 1986), the enhancement
of the glutamatergic signal may also have adverse effects
on memory, because high levels of glutamate are neu-
rotoxic (Lau and Tymianski 2010). Our results suggest
that fornix DBS does not influence glutamate-dependent
long-term potentiation, but also does not induce
excitotoxicity.
Contrary to this, fornix DBS did have an effect on
extracellular hippocampal acetylcholine and it might be
possible that increased c-Fos expression in the hippocam-
pus was mediated by enhanced acetylcholine levels
(Narimatsu et al. 2009). In an earlier study, we have shown
that fornix DBS was able to restore scopolamine-induced
memory deficits when stimulating the fornix for 5 min
during the acquisition and retention trial of the object
location task, a test of hippocampal-dependent memory
(Hescham et al. 2013). Potentially, the increased hip-
pocampal acetylcholine measured via microdialysis after
20 min facilitated the enhanced memory performance.
However, these results should be interpreted with caution,
since we did not include any memory tests in the present
study. The effect of DBS (20 min) on acetylcholine release
seemed to decline with continued stimulation. This tran-
sient effect can be explained by exhaustion of the acetyl-
choline pools that may take place after an enhanced release
for more than 20 min. Thus, chronic DBS might eventually
be associated with acetylcholine depletion. In this case,
either intermittent or closed-loop stimulation (Rosin et al.
2011) when applying chronic DBS of the fornix might be
necessary to maintain beneficial effects on memory
functions.
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